Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix, Digene, David Rigney, Dako Denmark

Affymetrix has received US Patent No. 7,399,584, “Method of comparing a target nucleic acid and a reference nucleic acid.” The patent describes a method of comparing a target nucleic acid with a reference sequence comprising a predetermined sequence of nucleotides. The method includes: a) hybridizing a sample comprising the target nucleic acid to an array of oligonucleotide probes immobilized on a solid support, where the array includes two complementary probe sets; and b) detecting a hybridization pattern of the oligonucleotide probes to the target nucleic acid and determining from the hybridization pattern whether a nucleotide in the target sequence is the same or different from the corresponding nucleotide in the reference sequence.

Digene of Gaithersburg, Md., has received US Patent No. 7,399,589, “Immunological detection of RNA:DNA hybrids on microarrays.” The patent claims a method for detecting or quantifying a target nucleic acid on a microarray by: a) hybridizing the target nucleic acid to a microarray-bound biomolecule probe, forming an immobilized RNA:DNA hybrid; b) hybridizing a detectably labeled biomolecule probe to a non-hybridized portion of the microarray-bound biomolecule probe, forming an immobilized RNA:DNA hybrid complex comprising the target nucleic acid, a detectably labeled biomolecule probe, and a microarray-bound biomolecule probe; c) detecting the target nucleic acid by measuring the immobilized RNA:DNA hybrid complex by binding the complex to a detectable antibody specifically reactive with an RNA:DNA hybrid; and d) detecting the detectably labeled biomolecule probe.

David Rigney of Austin, Tex., has received US Patent No. 7,400,981, “Systems, methods, and computer program product for analyzing microarray data.” The patent describes systems, methods, and computer program products for the analysis of gene expression data, especially data that have been acquired using microarray technologies. The system includes a computer having a central processing unit and a computer memory, which are used to run computer program modules. According to the methods, the computer program modules, along with experimental signal data representing relative concentrations of particular mRNA species, are loaded initially into the computer memory from a computer disk. One computer program module groups the mRNA species into clusters, each cluster being a subset of the mRNA species. Other computer program modules then associate multiple unique identifiers, corresponding to scientific publications describing gene structure and functions, with each of the genes in each of the clusters.

Dako Denmark of Glostrup, Denmark, has received US Patent No. 7,400,983, “Information notification sample processing system and methods of biological slide processing.” The patent describes an automated sample-processing system where samples are arranged on a carrier element; and a process operation control system that automatically processes the samples with an operationally influential exteriorly-consequential information monitor or a data-capture element. According to the patent, the sample-processing system may be applicable to immunohistochemistry techniques, as well fluorescent in situ hybridization and microarrays.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.